Matrix models also highlighted the ability of the combination of these 3 parameters to predict the occurrence of treatment failure and flares (Fig. S1): Treatment failure and RA flare occurred in 53% and 73% of patients with baseline DAS28 > 3.2 and presence of active synovitis on PDUS and SEMA4A concentrations > 94 ng/mL, respectively. The gene discussed is SEMA4A; the disease is rheumatoid arthritis.